JAGX stock forecast
Our latest prediction for Jaguar Health, Inc.'s stock price was made on the July 18, 2018 when the stock price was at 1.10$.
In the short term (2weeks), JAGX's stock price should outperform the market by 6.19%. During that period the price should oscillate between -11.32% and +23.10%.
In the medium term (3months), JAGX's stock price should outperform the market by 11.69%. During that period the price should oscillate between -23.28% and +64.87%.Get email alerts
Create a solid portfolio with JAGX
About Jaguar Health, Inc.
Jaguar Health, Inc. is a commercial stage pharmaceuticals company, which engages in the development of gastrointestinal products. Its products include Canalevia, Equilevia, and Neonorm. It operates through the Human Health and Animal Health segments. The Human Health segment manufactures human products and the ongoing advertising of Mytesi, which is used for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The Animal Health segment commercializes prescription and non-prescription products for companion and production animals. The company was founded by Lisa A. Conte on June 6, 2013 and is headquartered in San Francisco, CA.
At the moment the company generates 5M USD in revenues.
On its last earning announcement, the company reported a loss of -117.60$ per share.
The book value per share is 0.28$
Three months stock forecastJuly 18, 2018
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|